| 摘要 |
<p>The present invention provides methods for treating Parkinson's disease by administering to an afflicted host pharmaceutical compositions containing a therapeutically effective amount of urine peptide fractions containing 3-[N-phenylacetylaminopiperidine]-2,6-dion. The therapeutically effective urine peptide fractions of this invention, termed Antineoplastons A2 and A5, are obtained by two separate processes: Antineoplaston A2 is prepared by providing a volume of urine; separating from the urine particulate matter and matter having a molecular weight greater than about 5000; acidifying the urine; separating from the acidified urine any precipitated matter; introducing the acidified urine to a first chromatography column containing a polymeric resin adsorbent; eluting the column to recover an eluate; adjusting the pH of the eluate to between about 2 and 8; introducing the adjusted eluate to a second chromatography column; and recovering the peptide fraction containing the compound 3-[N-phenylacetylaminopiperidine[-2,6-dion. Antineoplaston A5 is prepared by providing a volume of urine; separating from the urine particulate matter and matter having a molecular weight greater than about 5000; acidifying the urine; separating from the acidified urine any precipitated matter; introducing the acidified urine to a chromatography column; eluting the column with a lower alkyl alcohol having from 1 to 8 carbon atoms; and recovering the peptide fraction containing the compound 3-[N-phenylacetylaminopiperidine]-2,6-dion.</p> |
